Health systems

Cancer care is at a pivotal moment with rapid and abundant advancements. While this is promising, keeping up can be complex. Health systems work tirelessly to improve outcomes for patients while supporting those who provide their care. Exact Sciences helps that happen.

The fight against cancer is tough, but together, we’re tougher.

A health care provider seated at a conference table with colleagues having a discussion.
Enhancing care together

Health systems need a partner that understands the business they run and the service they provide. Exact Sciences equips health systems with a portfolio of tools that can amplify their impact. That means rendering cancer powerless through early detection, innovative screening solutions, and best-in-class genomic testing — at speed and at scale.

We’ll collaborate with you to help improve risk profiling, treatment plans, and patient adherence and outcomes. We'll also help address challenges that impact patient care, including clinician and staff workload, operational and workflow efficiencies, and health equity.

A group of health care staff sitting at a conference table having a discussion.
Colorectal cancer screening solutions
Boosting colorectal cancer screening rates can improve health system quality measures and patient outcomes.1,2 With the Cologuard® test, providers can engage average risk patients 45 and over in their own health with a convenient, cost-effective option that offers best-in-class detection and superior sensitivity to FIT.3 Exact Sciences has a strong history of launching screening protocols that work for everyone – and constantly applying customer feedback to help health systems advance the standard of care. 
An Exact Sciences lab technician opening an OncoExTra test kit box.
Precision Oncology solutions

The Exact Sciences Precision Oncology portfolio doesn't stop with a test's science. It also reflects the realities of the clinical setting and what providers can face in ordering tests and delivering results to patients. Pairing comprehensive, world-class genomic tests like Oncotype DX® test with a connected digital infrastructure helps create a complete picture of each patient’s unique cancer with ease and efficiency. That frees providers and their patients to focus on what matters most — the best way forward.

We’re equipped to integrate our solutions into your workflows, streamlining your genomic cancer testing and helping you match your patients with emerging personalized treatments.

References

  1. Prince M, Lester L, Chiniwala R, Berger B. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. World J Gastroenterol. 2017;23(3):464-471.
  2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2022;72(1):7-33.
  3. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.

Cologuard Indications and Important Risk Information


The Cologuard® test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by colonoscopy. The Cologuard test is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. The Cologuard test is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

The Cologuard test is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

Positive Cologuard results should be referred to colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

False positives and false negatives do occur. In a clinical study, 13% of patients without colorectal cancer or advanced adenomas received a positive result (false positive) and 8% of patients with cancer received a negative result (false negative). The clinical validation study was conducted in patients 50 years of age and older. Cologuard test performance in patients ages 45 to 49 years was estimated by sub-group analysis of near-age groups.

Cologuard test performance when used for repeat testing has not been evaluated or established. Rx only